Health Council Advises Brazil to Break Patent on Three AIDS Drugs

    Brazil should break the patents on three HIV/AIDS drugs, whose cost could jeopardize national anti-HIV efforts, a Brazilian health agency has advised .

    The recommendation of the Brazilian National Health Council on August 11 would allow the country to make generic HIV drugs that are much cheaper than their brand name versions.


    The council says this year alone Brazil will spend US$ 420 million buying drugs for 136,000 patients. Eighty per cent of this will be spent on three drugs: Lopinavir, made by Abbott Laboratories, Nelfinavir by Merck Sharp and Tenofovir by Gilead.


    The high cost of brand-name drugs is threatening the sustainability of the Brazilian Program for the Combat of AIDS, which is widely regarded as a model for fighting HIV/AIDS in developing countries, says the council.


    For several months now, the government has been negotiating with the pharmaceutical companies that hold the patents to reduce the price of the three drugs.


    Under the internationally agreed TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement, if the nation’s health is at threat, a developing country can invoke a ‘compulsory license’ allowing them to make drugs without paying the patent-holder.


    Brazil’s 1996 intellectual property law also allows patents to be broken when companies use exploitative pricing policies.


    Brazil threatened three years ago to break Nelfinavir’s patent, but it eventually negotiated a lower price with the drug company. Earlier this year, the country said it would break the patent on Lopinavir, a threat it dropped after Abbott Laboratories agreed to drop the price of the drug from US$ 1.17 to US$ 0.68 for one capsule.


    But last week, an announcement from Brazilian public laboratories that they could make the drug for US$ 0.40 kick-started new negotiations.


    Because of intense price negotiations and the volume of drugs it buys, Brazil pays far less than other Latin American countries do for HIV/AIDS drugs. For Lopinavir, for example, Mexico pays US$ 2.40 per capsule and Argentina US$ 1.97.


    On August 11, the council recommended that Brazil immediately begin producing the drugs locally, strengthen state laboratories and provide more financial resources for research.


    It added that any commercial retaliation on the part of the companies against Brazil for breaking the patents should be considered an illegal act.


    Council member Carlos Duarte says the Brazilian health ministry has 30 days to approve or suggest changes to the council’s recommendation.


    The National Health Council is composed of representatives of consumers, government officials and companies.
     
    This article appeared originally in Science and Development Network – www.scidev.net.

    Tags:

    • Show Comments (0)

    Your email address will not be published. Required fields are marked *

    comment *

    • name *

    • email *

    • website *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Ads

    You May Also Like

    Despite Tax Break, Brazil Scientists Still Drowning in Red Tape

    Researchers in Brazil will no longer be hit with big import duties on research ...

    An Yanomami Indian from Brazil

    Indians Advocate Plurinational States Involving Brazil and Neighbors

    Indigenous peoples from Brazil and neighboring countries would like to turn Latin American nations into ...

    Delta Daily from Atlanta to Rio, Brazil

    Whether hitting the famous beaches at Copacabana or Ipanema, ascending the rocky spire of ...

    For the Empowerment of Women

    In the sixties and seventies, despite the military dictatorship, and influenced by the civil ...

    Brazilian business

    Brazil Top 10 in Entrepreneurship. 13% of Brazilians Have Own Business

    In 2007, Brazil has come closer to the main countries in entrepreneurship in the ...

    José Serra

    Brazilian Presidential Candidate Serra: a Life of Opposition and Solid Education

    Brazilian presidential candidate José Serra was born into a working-class family of Italian immigrants ...

    Brazil Needs 2000 Additional Federal Judges

    At a meeting with the United Nations’s special rapporteur, Leandro Despouy, Brazil’s president of ...

    Brazil’s Petrobras Has Big Plans and US$ 17 Billion to Spend in 2006

    Petrobras – Brazilian Petroleum S.A. – plans to invest US$ 17.4 billion next year ...

    Brazil to Coordinate South American Fight Against Sex-Tourism

    Representatives of over 45 countries are participating, in Brazil, in the 2nd Annual Meeting ...

    Prudente back as Legislative Assembly's president

    Bar Association Wants 10 Brasília’s Assemblymen Ousted

    This past December 16, the Federal District Legislative Assembly, which like other legislative bodies ...